Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dyva-AAGG: Anti-angiogenic therapy-induced micro- and macrovascular dysfunction
2011-002387-24Phase 4Completed
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Jul 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of bevacizumab, sunitinib, sorafenib, temsirolimus and everolimus in kidney cancer, pancreatic cancer (PC) and gastrointestinal cancer (5 arms), sponsored by Centre Hospitalier Universitaire d'Angers. Started Jul 2011; status: completed.
02
Drugs
bevacizumabsunitinibsorafenibtemsirolimuseverolimus
03
Conditions
kidney cancerpancreatic cancer (PC)gastrointestinal cancer
Beyond the preview
Go deeper on 2011-002387-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002387-24.